Aroa Biosurgery (ASX:ARX) spent years selling a regenerative tissue platform without turning a profit. The year to 31 March 2026 changed that, with the company moving into the black on higher Revenue and a far stronger cash position. In early September 2026 it published clinical registry data supporting its lead surgical product, the kind of evidence that underpins hospital adoption. With a Market Capitalisation near A$185 million as at 11 September 2026, Aroa is a commercial-stage medical technology Business rather than a pre-revenue biotech, a distinction that matters when weighing what could move the shares.

Latest Development

On 3 September 2026 Aroa released an interim analysis from the MASTRR Registry, which it described as the largest published prospective analysis of a bioscaffold used in in-patient soft tissue reconstruction. The results appeared in the Journal Advances in Therapy.

The analysis covered 411 patients and 474 soft tissue defects across 10 United States centres, with median follow-up of 27 weeks. Deep tissue infection was reported in 0.7 per cent of patients and superficial infection in 2.9 per cent, and the company stated that no infections were definitely attributed to Myriad. The patient group was not straightforward: 59 per cent were ASA Class III or IV, 35 per cent had diabetes and 89 per cent of defects were clean-contaminated or contaminated. Enrolment has since passed 550 patients, with approval for up to 800 across 15 sites.

Company Overview

Aroa develops soft tissue repair and wound management products from its proprietary AROA ECM platform. The commercial range spans Endoform for acute and chronic wound management; the Myriad family of surgical bioscaffolds, comprising Myriad Matrix, Myriad Morcells, Myriad Morcells Fine and Myriad Meshed; Symphony, which pairs a cellular tissue product with hyaluronic acid; and reinforced bioscaffolds for hernia repair and abdominal wall reconstruction.

The company listed on the ASX in July 2020 and says more than 7.5 million of its devices have been used globally.

Financial and Operational Position

Aroa reached profitability in FY2026. Market Index records revenue of $86.6 million for the twelve months to 31 March 2026, up from $77.0 million a year earlier, with EBITDA of $10.0 million against $2.1 million and a net profit of $3.9 million reversing a $3.5 million loss. Cash improved to $17.6 million from $7.3 million.

Within that, Myriad sales grew 54 per cent in FY2026 on the company's own figures, pointing to the surgical Franchise rather than wound care as the driver of the change. About 345 million shares are on issue. No Dividend has been paid.

What Investors May Watch Next

The MASTRR Registry continues to enrol and is approved to run to 800 patients across 15 sites, so further interim readouts are possible. Continued growth in Myriad, the traction achieved by Symphony and the reinforced bioscaffold range, and whether a first full year of profitability repeats in FY2027 are the practical markers.

Aroa held its Annual General Meeting on 19 August 2026. The half-year result covering the six months to 30 September 2026 is the next scheduled financial disclosure.

Risks

Sales are concentrated in the United States, exposing the company to that market's reimbursement settings and hospital purchasing cycles as well as to currency movements. Registry data is observational rather than randomised, which limits how far it can be pushed with clinicians.

Competing bioscaffolds are established products, and the Margin of profitability is thin: a net profit of $3.9 million leaves little cushion if growth slows or costs rise.

Conclusion

Aroa enters September 2026 holding two things a small-cap medical technology company rarely has at once: a maiden profit and fresh clinical evidence behind its growth product. Whether it holds a place on watchlists through the rest of 2026 may depend less on the registry headlines than on whether Myriad's 54 per cent growth rate is sustained, and on whether FY2026 profitability proves a starting point rather than a peak.